Breast cancer statistics 2024
2024/10/01 by Angela N. Giaquinto, Hyuna Sung, Lisa A. Newman +5 · 33 citations
Medicine · #Global Cancer Incidence and Screening #Cancer Risks and Factors #Colorectal Cancer Screening and Detection
paper · pdf · doi:10.3322/caac.21863
Abstract
This is the American Cancer Society's biennial update of statistics on breast cancer among women based on high-quality incidence and mortality data from the National Cancer Institute and the Centers for Disease Control and Prevention. Breast cancer incidence continued an upward trend, rising by 1% annually during 2012-2021, largely confined to localized-stage and hormone receptor-positive disease. A steeper increase in women younger than 50 years (1.4% annually) versus 50 years and older (0.7%) overall was only significant among White women. Asian American/Pacific Islander women had the fastest increase in both age groups (2.7% and 2.5% per year, respectively); consequently, young Asian American/Pacific Islander women had the second lowest rate in 2000 (57.4 per 100,000) but the highest rate in 2021 (86.3 per 100,000) alongside White women (86.4 per 100,000), surpassing Black women (81.5 per 100,000). In contrast, the overall breast cancer death rate continuously declined during 1989-2022 by 44% overall, translating to 517,900 fewer breast cancer deaths during this time. However, not all women have experienced this progress; mortality remained unchanged since 1990 in American Indian/Alaska Native women, and Black women have 38% higher mortality than White women despite 5% lower incidence. Although the Black-White disparity partly reflects more triple-negative cancers, Black women have the lowest survival for every breast cancer subtype and stage except localized disease, with which they are 10% less likely to be diagnosed than White women (58% vs. 68%), highlighting disadvantages in social determinants of health. Progress against breast cancer could be accelerated by mitigating racial, ethnic, and social disparities through improved clinical trial representation and access to high-quality screening and treatment.
Citations
Cited by
- Cancer statistics, 2026
- Cancer treatment and survivorship statistics, 2025
- How hazard ratios can mislead and why it matters in practice
- Dataset-Origin Signatures and Shortcut Learning in Screening Mammography AI: A Cross-Dataset Case Study
- Surface Marker Identification to Capture Live Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer
- MechanoAge, a machine learning platform to identify individuals susceptible to breast cancer based on mechanical properties of single cells
- Cancer Type–Specific Contributions to the Reduction in Cancer Mortality Gap Between Black Individuals and White Individuals
- The role of tumor microenvironment and immune cell crosstalk in triple-negative breast cancer (TNBC): Emerging therapeutic opportunities
- Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. [europepmc]
- The Effect of Ionising Radiation on the Properties of Tumour-Derived Exosomes and Their Ability to Modify the Biology of Non-Irradiated Breast Cancer Cells-An In Vitro Study. [europepmc]
- Cancer statistics, 2025. [europepmc]
- Statins as Secondary Preventive Agent to Limit Breast Cancer Metastatic Outgrowth. [europepmc]
- Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. [europepmc]
- Cancer statistics for African American and Black people, 2025. [europepmc]
- Bovine Leukemia Virus and Human Breast Cancer: A Review of Clinical and Molecular Evidence. [europepmc]
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. [europepmc]
- Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer. [europepmc]
- The Application of Dendritic Cells Vaccines in Tumor Therapy and Their Combination with Biomimetic Nanoparticles. [europepmc]
- Advancements in Cell Membrane-Derived Biomimetic Nanotherapeutics for Breast Cancer. [europepmc]
- Cancer treatment and survivorship statistics, 2025. [europepmc]
- Weighing the evidence on costs and benefits of polygenic risk-based approaches in clinical practice: A systematic review of economic evaluations. [europepmc]
- Breast Cancer Incidence Trends in Older US Women by Race, Ethnicity, Geography, and Stage. [europepmc]
- Prognostic Relevance of Inflammatory Cytokines Il-6 and TNF-Alpha in Patients with Breast Cancer: A Systematic Review and Meta-Analysis. [europepmc]
- Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond. [europepmc]
- Recreational physical activity and health-related quality of life among breast cancer survivors: a systematic review. [europepmc]
- Current Bioinformatics Tools in Precision Oncology. [europepmc]
- Increasing incidence of breast cancer in young women over time. [europepmc]
- Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectives. [europepmc]
- FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer. [europepmc]
- Lobular breast cancer statistics, 2025. [europepmc]
- Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring. [europepmc]
- Overcoming Therapeutic Resistance in Triple-Negative Breast Cancer: Targeting the Undrugged Kinome. [europepmc]
- Cancer statistics, 2026. [europepmc]
Related